- I-Mab at Jefferies London Healthcare Conference TranscriptNov 14, 2023
- Half Year 2023 I-Mab Earnings Call TranscriptAug 17, 2023$2.3 (-2.95%)Earnings
- Full Year 2022 I-Mab Earnings Call TranscriptMar 31, 2023$3.46 (-1.70%)Earnings
- I-Mab Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab Call TranscriptSep 12, 2022
- Half Year 2022 I-Mab Earnings Call TranscriptAug 30, 2022$5.98 (+2.57%)Earnings
- I-Mab R&D Day TranscriptJul 20, 2022
- I-Mab TJD5 Phase 2 Clinical Trial Data Update Call TranscriptMay 27, 2022
- Full Year 2021 I-Mab Earnings Call TranscriptMar 29, 2022$19.39 (+15.07%)Earnings
- I-Mab at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- I-Mab Corporate Call TranscriptDec 21, 2021
- I-Mab Most Recent Clinical Data Update Conference Call -- English Session TranscriptDec 14, 2021
- I-Mab and Jumpcan To Announce its Strategic Commercial Partnership on Eftansomatropin Alfa - Special Call TranscriptNov 10, 2021
- Half Year 2021 I-Mab Earnings & Corporate Progress Update Conference Call TranscriptAug 31, 2021
- I-Mab to Discuss Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021 Call TranscriptJun 07, 2021
- I-Mab at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- I-Mab Corporate Analyst Meeting TranscriptApr 26, 2021
- Full Year 2020 I-Mab Earnings Call TranscriptMar 29, 2021$44.38 (-4.80%)Earnings
- IMAB Lemzoparlimab Phase 1 Clinical Trial Data Update Conference Call TranscriptNov 13, 2020
- I-Mab SITC Data Conference Call TranscriptNov 09, 2020
- I-Mab Company Update Conference Call TranscriptSep 04, 2020
- Half Year 2020 I-Mab Earnings Call TranscriptAug 31, 2020$39.44 (+27.23%)Earnings
- I-Mab Update Conference Call TranscriptMay 28, 2020
- I-Mab at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Full Year 2019 I-Mab Earnings Call TranscriptMar 31, 2020$13 (+4.00%)Earnings
I-Mab at JPMorgan Healthcare Conference (Virtual) Transcript
Hello, everyone. Welcome to the 2022 JPMorgan Global Healthcare Conference. I'm Lingling Chen from China healthcare investment banking team. And today, we are very honored without Dr. Jingwu Zang from I-Mab biopharma to present at our conference. I-Mab is a biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics. Since its establishment, I-Mab has experienced tremendous growth and has developed an innovative pipeline of over 10 clinical stage assets. The company has also been listed on the NASDAQ since January 2020. Our speaker today, Dr. Jingwu Zang is the Founder and Chairman of the company with over 30 years of experience in the academia and industry.
Now I'll pass the stage on to Dr. Zang for the presentation. Thank you.
Hi, I'm Jingwu Zang, Founder, Chairman and the Acting CEO of I-Mab. First of all, I'd like to thank you all for joining this virtual meeting today. This is a great opportunity for me to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)